Xeris Historical Balance Sheet

XERS Stock

USD 3.29 0.05 1.50%

Trend analysis of Xeris Pharmaceuticals balance sheet accounts such as Total Assets of 203.3 M, Other Current Liab of 96.8 M, Total Current Liabilities of 114.9 M or Other Liab of 35.3 M provides information on Xeris Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Xeris Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Xeris Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Xeris Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Xeris Pharmaceuticals is a good buy for the upcoming year.

Xeris Pharmaceuticals Inventory

46.9 Million

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

About Xeris Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Xeris Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Xeris Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Xeris Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Xeris currently owns. An asset can also be divided into two categories, current and non-current.

Xeris Pharmaceuticals Balance Sheet Chart

At this time, Xeris Pharmaceuticals' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 5.7 M in 2025, despite the fact that Total Stockholder Equity is likely to grow to (7.4 M).

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Xeris Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Xeris Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Xeris Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Xeris Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Xeris Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Xeris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.At this time, Xeris Pharmaceuticals' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 5.7 M in 2025, despite the fact that Total Stockholder Equity is likely to grow to (7.4 M).

	2023	2024	2025 (projected)
Other Current Liabilities	80.1M	92.2M	96.8M
Total Assets	322.6M	371.0M	203.3M

Other Current Liab Total Assets

Xeris Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity
Total Assets		0.91	0.9	0.57	0.94	-0.5	0.93	0.85	0.85	-0.96	0.8	0.87	0.91	0.37	0.79	0.74	0.85	0.91	0.88	0.95	0.89	0.92	0.99	0.9	0.82	0.78
Other Current Liab	0.91		1.0	0.37	0.97	-0.63	0.99	0.9	0.97	-0.96	0.96	0.75	0.99	0.49	0.91	0.62	0.97	0.94	0.98	0.9	0.9	0.84	0.91	0.99	0.95	0.67
Total Current Liabilities	0.9	1.0		0.36	0.95	-0.61	0.99	0.88	0.98	-0.95	0.96	0.72	0.98	0.5	0.93	0.61	0.98	0.93	0.98	0.88	0.9	0.83	0.9	0.99	0.97	0.68
Total Stockholder Equity	0.57	0.37	0.36		0.47	0.34	0.4	0.51	0.34	-0.53	0.22	0.53	0.34	-0.12	0.21	0.89	0.27	0.54	0.33	0.29	0.66	0.59	0.6	0.29	0.25	0.61
Other Liab	0.94	0.97	0.95	0.47		-0.58	0.98	0.88	0.9	-0.96	0.9	0.86	0.97	0.48	0.81	0.69	0.89	0.93	0.92	0.91	0.89	0.84	0.91	0.96	0.85	0.68
Net Tangible Assets	-0.5	-0.63	-0.61	0.34	-0.58		-0.64	-0.37	-0.52	0.52	-0.58	-0.56	-0.7	-0.61	-0.69	0.08	-0.65	-0.41	-0.66	-0.72	-0.27	-0.46	-0.42	-0.7	-0.64	-0.11
Property Plant And Equipment Net	0.93	0.99	0.99	0.4	0.98	-0.64		0.88	0.95	-0.96	0.93	0.81	0.99	0.52	0.91	0.63	0.96	0.93	0.98	0.91	0.89	0.86	0.91	0.99	0.94	0.67
Current Deferred Revenue	0.85	0.9	0.88	0.51	0.88	-0.37	0.88		0.9	-0.93	0.85	0.62	0.82	0.17	0.75	0.75	0.82	0.95	0.84	0.77	0.96	0.85	0.9	0.85	0.82	0.76
Net Debt	0.85	0.97	0.98	0.34	0.9	-0.52	0.95	0.9		-0.93	0.97	0.6	0.93	0.42	0.91	0.6	0.97	0.93	0.96	0.82	0.91	0.79	0.88	0.95	0.97	0.68
Retained Earnings	-0.96	-0.96	-0.95	-0.53	-0.96	0.52	-0.96	-0.93	-0.93		-0.88	-0.8	-0.94	-0.34	-0.84	-0.75	-0.9	-0.97	-0.93	-0.91	-0.95	-0.91	-0.97	-0.94	-0.88	-0.76
Accounts Payable	0.8	0.96	0.96	0.22	0.9	-0.58	0.93	0.85	0.97	-0.88		0.57	0.93	0.56	0.86	0.48	0.94	0.86	0.92	0.81	0.83	0.69	0.81	0.94	0.92	0.63
Cash	0.87	0.75	0.72	0.53	0.86	-0.56	0.81	0.62	0.6	-0.8	0.57		0.81	0.4	0.63	0.66	0.66	0.72	0.73	0.85	0.68	0.79	0.79	0.78	0.61	0.56
Non Current Assets Total	0.91	0.99	0.98	0.34	0.97	-0.7	0.99	0.82	0.93	-0.94	0.93	0.81		0.59	0.92	0.56	0.96	0.89	0.98	0.91	0.84	0.83	0.88	0.99	0.94	0.62
Non Currrent Assets Other	0.37	0.49	0.5	-0.12	0.48	-0.61	0.52	0.17	0.42	-0.34	0.56	0.4	0.59		0.51	-0.13	0.51	0.19	0.51	0.45	0.17	0.27	0.27	0.52	0.49	0.12
Other Assets	0.79	0.91	0.93	0.21	0.81	-0.69	0.91	0.75	0.91	-0.84	0.86	0.63	0.92	0.51		0.44	0.98	0.81	0.98	0.81	0.77	0.81	0.79	0.93	0.99	0.56
Cash And Short Term Investments	0.74	0.62	0.61	0.89	0.69	0.08	0.63	0.75	0.6	-0.75	0.48	0.66	0.56	-0.13	0.44		0.52	0.8	0.57	0.52	0.87	0.73	0.78	0.57	0.5	0.79
Net Receivables	0.85	0.97	0.98	0.27	0.89	-0.65	0.96	0.82	0.97	-0.9	0.94	0.66	0.96	0.51	0.98	0.52		0.89	0.99	0.85	0.84	0.81	0.85	0.97	1.0	0.63
Common Stock Total Equity	0.91	0.94	0.93	0.54	0.93	-0.41	0.93	0.95	0.93	-0.97	0.86	0.72	0.89	0.19	0.81	0.8	0.89		0.9	0.83	0.98	0.85	0.93	0.91	0.87	0.76
Common Stock Shares Outstanding	0.88	0.98	0.98	0.33	0.92	-0.66	0.98	0.84	0.96	-0.93	0.92	0.73	0.98	0.51	0.98	0.57	0.99	0.9		0.88	0.86	0.86	0.88	0.98	0.99	0.64
Non Current Liabilities Total	0.95	0.9	0.88	0.29	0.91	-0.72	0.91	0.77	0.82	-0.91	0.81	0.85	0.91	0.45	0.81	0.52	0.85	0.83	0.88		0.77	0.85	0.91	0.91	0.82	0.67
Capital Surpluse	0.89	0.9	0.9	0.66	0.89	-0.27	0.89	0.96	0.91	-0.95	0.83	0.68	0.84	0.17	0.77	0.87	0.84	0.98	0.86	0.77		0.87	0.94	0.85	0.83	0.82
Other Current Assets	0.92	0.84	0.83	0.59	0.84	-0.46	0.86	0.85	0.79	-0.91	0.69	0.79	0.83	0.27	0.81	0.73	0.81	0.85	0.86	0.85	0.87		0.93	0.82	0.81	0.75
Other Stockholder Equity	0.99	0.91	0.9	0.6	0.91	-0.42	0.91	0.9	0.88	-0.97	0.81	0.79	0.88	0.27	0.79	0.78	0.85	0.93	0.88	0.91	0.94	0.93		0.87	0.83	0.82
Total Liab	0.9	0.99	0.99	0.29	0.96	-0.7	0.99	0.85	0.95	-0.94	0.94	0.78	0.99	0.52	0.93	0.57	0.97	0.91	0.98	0.91	0.85	0.82	0.87		0.95	0.64
Property Plant And Equipment Gross	0.82	0.95	0.97	0.25	0.85	-0.64	0.94	0.82	0.97	-0.88	0.92	0.61	0.94	0.49	0.99	0.5	1.0	0.87	0.99	0.82	0.83	0.81	0.83	0.95		0.62
Preferred Stock Total Equity	0.78	0.67	0.68	0.61	0.68	-0.11	0.67	0.76	0.68	-0.76	0.63	0.56	0.62	0.12	0.56	0.79	0.63	0.76	0.64	0.67	0.82	0.75	0.82	0.64	0.62

Click cells to compare fundamentals

Xeris Pharmaceuticals Account Relationship Matchups

Xeris Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	109.0M	159.2M	344.5M	322.6M	371.0M	203.3M
Other Current Liab	25.1M	70.1M	65.9M	80.1M	92.2M	96.8M
Total Current Liabilities	27.3M	28.2M	73.6M	95.2M	109.5M	114.9M
Total Stockholder Equity	14.4M	33.8M	45.2M	(6.8M)	(7.8M)	(7.4M)
Other Liab	8.9M	10.2M	42.0M	29.2M	33.6M	35.3M
Net Tangible Assets	14.4M	33.8M	(59.1M)	(98.3M)	(88.5M)	(84.0M)
Property Plant And Equipment Net	7.9M	6.7M	28.4M	29.2M	33.6M	35.2M
Net Debt	38.8M	49.4M	76.1M	161.7M	186.0M	195.3M
Retained Earnings	(246.2M)	(337.4M)	(554.8M)	(617.0M)	(555.3M)	(527.6M)
Accounts Payable	3.1M	8.9M	4.6M	11.6M	13.3M	14.0M
Cash	19.5M	37.6M	122.0M	67.4M	77.6M	67.2M
Non Current Assets Total	21.5M	6.9M	157.7M	166.3M	191.3M	200.9M
Non Currrent Assets Other	(13.0M)	4.7M	267K	4.5M	5.2M	5.5M
Other Assets	420K	232K	829K	4.7M	5.4M	5.7M
Cash And Short Term Investments	75.5M	133.8M	122.0M	72.5M	83.3M	98.0M
Net Receivables	6.9M	17.5M	30.8M	39.2M	45.1M	47.3M
Liabilities And Stockholders Equity	109.0M	159.2M	344.5M	322.6M	371.0M	203.3M
Non Current Liabilities Total	67.2M	97.2M	225.7M	234.2M	269.3M	143.7M
Other Current Assets	3.2M	4.6M	9.3M	5.8M	6.6M	4.3M
Other Stockholder Equity	371.1M	555.4M	600.0M	610.3M	701.8M	357.4M
Total Liab	94.6M	125.4M	299.3M	329.4M	378.8M	397.7M
Property Plant And Equipment Gross	6.7M	10.8M	28.4M	35.2M	40.5M	42.5M
Total Current Assets	87.5M	152.2M	186.8M	156.3M	179.7M	132.6M
Accumulated Other Comprehensive Income	43K	6K	(23K)	(25K)	(28.8K)	(30.2K)
Common Stock	2K	3K	6K	14K	16.1K	16.9K
Property Plant Equipment	7.9M	6.7M	6.6M	9.5M	10.9M	11.5M
Net Invested Capital	120.8M	183.3M	232.3M	184.2M	211.8M	132.4M
Net Working Capital	124.0M	63.6M	113.2M	61.1M	70.2M	89.4M
Short Long Term Debt Total	58.3M	87.0M	198.1M	229.2M	263.6M	148.6M
Long Term Debt	87.0M	88.1M	187.1M	190.9M	219.6M	117.9M
Short Term Investments	96.2M	35.2M	0.0	5.0M	4.5M	4.3M
Capital Stock	3K	6K	13K	14K	16.1K	9.5K
Non Current Liabilities Other	3.5M	30.2M	25.7M	6.2M	7.2M	14.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Xeris Historical Balance Sheet

Xeris Pharmaceuticals Inventory

46.9 Million

About Xeris Balance Sheet Analysis

Xeris Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Xeris Pharmaceuticals balance sheet Correlations

Xeris Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Xeris Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Xeris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Property Plant And Equipment Gross	+ 1.0	Net Receivables
Other Stockholder Equity	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Other Current Liab
Non Current Assets Total	+ 0.99	Other Current Liab
Total Liab	+ 0.99	Other Current Liab

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net
Retained Earnings	- 0.96	Other Liab
Retained Earnings	- 0.96	Other Current Liab
Retained Earnings	- 0.96	Total Assets